U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07354295) titled 'Multimodal AI-based Therapy Response Prediction and Risk Stratification for Esophageal Cancer' on Jan. 12.
Brief Summary: Our AI predictive model based on data modalities available, including radiomics, pathomics, genomics, and multi-omics approaches, each providing distinct insights into tumor characteristics, wich therefore can predict treatment response and prognosis.
Study Start Date: Sept. 01, 2025
Study Type: OBSERVATIONAL
Condition:
Esophageal Cancer
Recruitment Status: RECRUITING
Sponsor: Tongji Hospital
Information provided by (Responsible Party): Shu Peng, Tongji Hospital
Disclaimer: Curated by HT Syndication....